DALLAS – Baylor Scott & White has enrolled the world’s first patients in a new clinical trial of a type of Remdesivir treatment that can be given when a person has only mild symptoms of COVID-1
The hope is that the treatment will prevent the progression of the disease and prevent people from having to be hospitalized.
Baylor Scott & White is one of only three hospital systems in the world to participate in this initial phase of testing that could lead to a drug that will help keep high-risk people out of the hospital.
Dr Steven Davis, with Baylor Scott and White, says it’s encouraging now to get to work with patients before they become seriously ill from COVID-19.
“It is refreshing to see patients on an outpatient basis and make a difference that prevents them from progressing to a more serious stage,” he said.
Remdesivir already has emergency approval for use in hospitalized patients. Hence, it is administered through an IV.
The phase 2 study will determine whether the drug can be administered as an aerosol. It is given to volunteers as an asthma drug.
“It enters the lungs directly where the virus attempts to attack,” explained Dr. Davis, “and as an antiviral, it attempts to interfere with attacks at those local levels. It is sent directly to the site of activity with the COVID-19 virus.”
Dr. Davis says the study began earlier this month. It is double-blind, so neither doctors nor patients know if they are receiving the drug or a placebo.
This is an early stage trial, so it aims to determine the correct dosage and any potential side effects.
Dr. Davis says most of the participants volunteer as a way to help others.
“If we can intervene earlier and prevent the need for hospitalization, we will do everyone a service,” he said.
Those interested in the COVID-19 testing research study can call 1-888-50-RESEARCH or visit bswhealth.com/research.
For patients interested in enrolling in this study, they can connect with any of the three emails below based on where they live.